These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 25611897)
1. Increased Notch1 expression is associated with poor overall survival in patients with ovarian cancer. Alniaimi AN; Demorest-Hayes K; Alexander VM; Seo S; Yang D; Rose S Int J Gynecol Cancer; 2015 Feb; 25(2):208-13. PubMed ID: 25611897 [TBL] [Abstract][Full Text] [Related]
2. [Expression of Notch1, Jagged1 and NICD in epithelial ovarian carcinomas and a preliminary study on the activity of gamma-secretase in epithelial ovarian carcinoma cell lines]. Feng Z; Wen H; Liao Q Zhonghua Fu Chan Ke Za Zhi; 2014 Oct; 49(10):780-6. PubMed ID: 25537253 [TBL] [Abstract][Full Text] [Related]
3. Notch 1 signaling is active in ovarian cancer. Rose SL; Kunnimalaiyaan M; Drenzek J; Seiler N Gynecol Oncol; 2010 Apr; 117(1):130-3. PubMed ID: 20060575 [TBL] [Abstract][Full Text] [Related]
4. Roles of E-cadherin and cyclooxygenase enzymes in predicting different survival patterns of optimally cytoreduced serous ovarian cancer patients. Taşkin S; Dünder I; Erol E; Taşkin EA; Kiremitçi S; Öztuna D; Sertçelik A Asian Pac J Cancer Prev; 2012; 13(11):5715-9. PubMed ID: 23317244 [TBL] [Abstract][Full Text] [Related]
5. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. Liu JF; Hirsch MS; Lee H; Matulonis UA Gynecol Oncol; 2009 Dec; 115(3):401-6. PubMed ID: 19796795 [TBL] [Abstract][Full Text] [Related]
6. Impact of obesity on operative morbidity and clinical outcome in primary epithelial ovarian cancer after optimal primary tumor debulking. Fotopoulou C; Richter R; Braicu EI; Kuhberg M; Feldheiser A; Schefold JC; Lichtenegger W; Sehouli J Ann Surg Oncol; 2011 Sep; 18(9):2629-37. PubMed ID: 21394662 [TBL] [Abstract][Full Text] [Related]
7. Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer. Previs RA; Kilgore J; Craven R; Broadwater G; Bean S; Wobker S; DiFurio M; Bae-Jump V; Gehrig PA; Secord AA Int J Gynecol Cancer; 2014 May; 24(4):670-5. PubMed ID: 24614825 [TBL] [Abstract][Full Text] [Related]
8. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival. Davidson B; Trope' CG; Wang TL; Shih IeM Gynecol Oncol; 2006 Dec; 103(3):814-9. PubMed ID: 16844205 [TBL] [Abstract][Full Text] [Related]
9. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer. Xu X; Deng F; Lv M; Ren B; Guo W; Chen X J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779 [TBL] [Abstract][Full Text] [Related]
10. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma. Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275 [TBL] [Abstract][Full Text] [Related]
11. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival. Stavnes HT; Holth A; Don T; Kærn J; Vaksman O; Reich R; Trope' CG; Davidson B Gynecol Oncol; 2013 May; 129(2):358-63. PubMed ID: 23438671 [TBL] [Abstract][Full Text] [Related]
12. PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors. Lohneis P; Darb-Esfahani S; Dietel M; Braicu I; Sehouli J; Arsenic R Anticancer Res; 2015 Nov; 35(11):6329-34. PubMed ID: 26504072 [TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium. Guan J; Darb-Esfahani S; Richter R; Taube ET; Ruscito I; Mahner S; Woelber L; Prieske K; Concin N; Vergote I; Van Nieuwenhuysen E; Achimas-Cadariu P; Glajzer J; Woopen H; Stanske M; Kulbe H; Denkert C; Sehouli J; Braicu EI J Cancer Res Clin Oncol; 2019 Apr; 145(4):1063-1073. PubMed ID: 30810838 [TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma. Lee M; Nam EJ; Kim SW; Kim S; Kim JH; Kim YT Int J Gynecol Cancer; 2012 Nov; 22(9):1489-96. PubMed ID: 23095773 [TBL] [Abstract][Full Text] [Related]
15. A detailed study of patients and tumor characteristics of epithelial ovarian cancer in Saudi women. Al-Badawi IA; Munkarah AR; Tulbah A; Babic II; Al Husaini H; Ahmad S Int J Gynecol Cancer; 2013 Mar; 23(3):456-60. PubMed ID: 23360812 [TBL] [Abstract][Full Text] [Related]
16. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma. Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277 [TBL] [Abstract][Full Text] [Related]
17. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976 [TBL] [Abstract][Full Text] [Related]
18. Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC). Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X J Ovarian Res; 2017 Jan; 10(1):7. PubMed ID: 28122595 [TBL] [Abstract][Full Text] [Related]
19. ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer. Muallem MZ; Braicu I; Nassir M; Richter R; Sehouli J; Arsenic R Anticancer Res; 2014 Jan; 34(1):393-9. PubMed ID: 24403493 [TBL] [Abstract][Full Text] [Related]
20. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients. Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]